Want to see CSBR full AI Analyst Report?
Earnings Data
Report Date
Jul 16, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
―Last Year’s EPS
-0.07Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Q3 2026
Earnings Call Date:Mar 12, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed solid operational execution — record services revenue, ~32% growth in core study revenue, and a third consecutive positive adjusted EBITDA — alongside deliberate investments in data and a therapeutic subsidiary (Corellia). However, near-term challenges include a modest overall revenue decline (~3%) driven by absence of prior-year data license revenue, compression of gross margin (61% to 47%) driven in part by outsourced radiolabeling costs, and elevated operating expenses (~+36%). Data revenue remains early and variable, and Corellia funding timing is uncertain. On balance, the positive operational momentum and pathway to monetize data and Corellia slightly outweigh the near-term margin and timing headwinds.Company Guidance
Record Services Revenue and Core Study Growth
Total revenue of $16.6M for the quarter with core study (services) revenue a record $16.6M, up from $12.6M year-ago (~+32%), reflecting strong study execution and conversion of previously booked work.
Positive Adjusted EBITDA Momentum
Third consecutive quarter of positive adjusted EBITDA of $575k, and management remains on track for full-year positive adjusted EBITDA.
Operating Leverage and Efficiency
Growth in services delivered without material additions to headcount, indicating operating leverage and the ability to expand margins as the business scales.
Early Commercial Traction in Data Business
Closed a six-figure data deal in the quarter (expected to be recognized in Q4) and expects incremental revenue from a previously announced large data deal in Q4 — signs of early momentum in the nascent data platform.
Strategic Investments in Growth Vectors
Continued investments in the data platform, sequencing and related R&D, expansion of data business development and commercial teams, and development of radiopharmaceutical capabilities to enhance long-term growth potential.
Progress at Corellia (Target Discovery Subsidiary)
Corellia generating attractive data with positive feedback from potential VC and licensing partners; management plans to include funding in fiscal 2027 budget and may secure external funding to reduce internal EBITDA investment.
Solid Balance Sheet Positioning
Ended the quarter with $7.1M in cash, no debt, and net cash used in operating activities of $1.4M for the quarter, with management stating cash is within projected range.
CSBR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CSBR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 12, 2026 | $5.74 | $6.10 | +6.27% |
Dec 15, 2025 | $7.80 | $6.73 | -13.72% |
Sep 15, 2025 | $6.83 | $8.30 | +21.52% |
Jul 23, 2025 | $7.75 | $6.65 | -14.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Champions Oncology Inc (CSBR) report earnings?
Champions Oncology Inc (CSBR) is schdueled to report earning on Jul 16, 2026, After Close (Confirmed).
What is Champions Oncology Inc (CSBR) earnings time?
Champions Oncology Inc (CSBR) earnings time is at Jul 16, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CSBR EPS forecast?
Currently, no data Available